The Phase-III trial of TURKOVAC has launched in Azerbaijan
Within the framework of international clinical trials of first domestic inactivated vaccine-named TURKOVAC, which was developed by Turkish scientists with the support of TÜSEB, the booster Phase-III trials have launched in our brother country, Azerbaijan with the protocol signed by The President of TÜSEB Prof. Dr. Erhan Akdoğan and The Director of Baku Health Centre Asiman Hasanov.
The clinical trial of TURKOVAC, which commenced mass production following Emergency Use Authority in Türkiye on December 22, 2021 and has been started to use commonly, is first launched in Azerbaijan and it is the first clinical trial to be conducted abroad.
The President of TÜSEB Prof. Dr. Akdoğan noted “It is very important to make such a cooperation with Azerbaijan. As Turkish nations, we are happy and proud to show that we are always united and ready for the pandemics of the future.”
The Director of Baku Health Centre Asiman Hasanov stated “Our brother country Türkiye manufactured its own vaccine and used it effectively. Today, we start the Phase-III clinical trials of TURKOVAC in Azerbaijan.”
In the clinical trial, the Azerbaijani citizens, who were administered 2 doses of inactivated vaccines, can choose TURKOVAC as the 3rd dose. In order to include in the study, the terms are, to be between the ages of 18 – 59, to be administered 2 doses of inactivated vaccines, to spend at least 90 and maximum 270 days after the 2nd dose of vaccine, and not to undergo the disease before.
